Author

K. Mittal

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Approach:benchmark study· 1 Research Focus:ecology & biodiversity· 1 Organism:human· 1 Organism:non-human primate· 1 Approach:statistical model· 1

Frequent Co-Authors

J. Head· 2 shared N. Basu· 2 shared A. J. Murphy· 1 shared A. L. Christie· 1 shared A. L. Hong· 1 shared A. Marshall· 1 shared B. A. Leeper· 1 shared B. Crompton· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

J. Head

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Towards establishing a 24-hour, microplate-based, transcriptomics assay for rainbow trout embryos

N. Basu, A. Marshall, H. Marchand, E. Boulanger, K. Mittal, J. Head

This paper establishes a 24-hour, microplate-based transcriptomics assay for rainbow trout embryos to generate toxicological data efficiently and ethically.

bioRxiv · Jul 7, 2023 · PreprintPharmacology & Toxicology

Resource requirements for ecotoxicity testing: A comparison of traditional and new approach methods

K. Mittal, D. Crump, J. Head, M. Hecker, G. Hickey, S. Maguire, N. Hogan, J. Xia, N. Basu

This study compares resource requirements of traditional and new approach methods in ecotoxicity testing, finding NAMs are cheaper, use fewer animals, and are faster.

bioRxiv · Feb 24, 2022 · PreprintPharmacology & Toxicology

Targeting TRIP13 in Wilms Tumor with Nuclear Export Inhibitors

K. Mittal, B. P. Lee, G. W. Cooper, J. Shim, H. C. Jonus, W. J. Kim, M. Doshi, D. Almanza, B. D. Kynnap, A. L. Christie, X. Yang, G. S. Cowley, B. A. Leeper, C. L. Morton, B. Dwivedi, , A. L. Hong

This study identifies XPO1 inhibition with selinexor as a potential therapy for favorable histology Wilms tumors, showing synergy with doxorubicin in preclinical models.

bioRxiv · Feb 23, 2022Cancer Biology